KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Cash from Investing Activities (2016 - 2026)

Bristol Myers Squibb has reported Cash from Investing Activities over the past 18 years, most recently at -$131.0 million for Q1 2026.

  • Quarterly Cash from Investing Activities rose 73.75% to -$131.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.8 billion through Mar 2026, down 68.56% year-over-year, with the annual reading at -$4.1 billion for FY2025, 80.65% up from the prior year.
  • Cash from Investing Activities was -$131.0 million for Q1 2026 at Bristol Myers Squibb, up from -$1.5 billion in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $1.2 billion in Q4 2022 and troughed at -$19.6 billion in Q1 2024.
  • The 5-year median for Cash from Investing Activities is -$410.0 million (2023), against an average of -$1.7 billion.
  • Year-over-year, Cash from Investing Activities surged 202.49% in 2022 and then crashed 9241.9% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $1.2 billion in 2022, then crashed by 210.96% to -$1.3 billion in 2023, then skyrocketed by 85.44% to -$196.0 million in 2024, then plummeted by 643.88% to -$1.5 billion in 2025, then skyrocketed by 91.02% to -$131.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Cash from Investing Activities are -$131.0 million (Q1 2026), -$1.5 billion (Q4 2025), and -$1.7 billion (Q3 2025).